Logo image
Sign in
BEVACZIUMAB PLUS FOSBRETABULIN IN RECURRENT OVARIAN CANCER: OVERALL SURVIVAL AND EXPLORATORY ANALYSES OF A RANDOMIZED PHASE II NRG ONCOLOGY/GYNECOLOGIC ONCOLOGY GROUP STUDY
Journal article   Peer reviewed

BEVACZIUMAB PLUS FOSBRETABULIN IN RECURRENT OVARIAN CANCER: OVERALL SURVIVAL AND EXPLORATORY ANALYSES OF A RANDOMIZED PHASE II NRG ONCOLOGY/GYNECOLOGIC ONCOLOGY GROUP STUDY

Krishnansu S. Tewari, Michael W. Sill, Robert L. Coleman, Carol Aghajanian, Robert Mannel, Paul A. DiSilvestro, Matthew Powell, Leslie M. Randall, John Farley, Stephen C. Rubin, …
Gynecologic oncology, Vol.159(1), pp.79-87
07/26/2020
PMID: 32723679

Abstract

bevacizumab fosbretabulin ovarian cancer vascular disrupting agent

Metrics

5 Record Views

Details